Showing 3801-3810 of 9081 results for "".
- ODAC 2026 Adds Hands-On, High-Impact Workshopshttps://practicaldermatology.com/news/odac-2026-adds-hands-on-high-impact-workshops/2484689/The ODAC Dermatology Conference will return to Orlando, Florida, in 2026 with a refreshed slate of interactive, expert-led sessions that emphasize skill-building across medical, surgical, and aesthetic dermatology, organizers said in a press release. Scheduled for J
- Analysis: Machine Learning Model Outperforms Existing Melanoma Prognostic Toolshttps://practicaldermatology.com/news/analysis-machine-learning-model-outperforms-existing-melanoma-prognostic-tools/2484593/A new machine learning-based model may offer clinicians a more accurate method for predicting prognosis in patients with cutaneous melanoma, according to a study published in Experimental Dermatology.
- SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Creamhttps://practicaldermatology.com/news/scratch-ad-rapid-onset-anti-itch-and-anti-inflammatory-effects-of-ruxolitinib-cream/2484591/Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.
- Stapokibart Shows Efficacy and Safety in Elderly Patients With ADhttps://practicaldermatology.com/news/stapokibart-shows-efficacy-and-safety-in-elderly-patients-with-ad/2484589/This post hoc analysis evaluated the efficacy and safety of stapokibart, an anti–IL-4Rα monoclonal antibody, in elderly adults with moderate-to-severe atopic dermatitis—a population often characterized by more complex inflammatory signatures and comorbidities. The
- AI Model Accurately Scores Psoriasis Severity from Clinical Imageshttps://practicaldermatology.com/news/ai-model-accurately-scores-psoriasis-severity-from-clinical-images/2484588/A new study demonstrates the potential of artificial intelligence (AI) to improve the consistency and objectivity of psoriasis severity assessments based on 2D clinical images. Researchers for the study used the YOLOv8 deep lear
- Skin of Color Society Media Day Analyzes Latest Trendshttps://practicaldermatology.com/news/skin-of-color-society-media-day-analyzes-latest-trends/2484533/In an era of misinformation and viral skincare fads, the Skin of Color Society’s (SOCS) 8th Annual Media Day offered a timely and authoritative voice, gathering top board-certified dermatologists to address critical dermatologic topics relevant to patients with skin of color. From trending TikTok
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://practicaldermatology.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://practicaldermatology.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum